Last reviewed · How we verify
Metformin HCI XR
Metformin HCl XR reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.
Metformin HCl XR reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin HCI XR |
|---|---|
| Also known as | Extended Release Metformin |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and increasing peripheral glucose uptake and utilization. The extended-release (XR) formulation allows for once-daily dosing with improved gastrointestinal tolerability compared to immediate-release formulations. It does not stimulate insulin secretion, making it suitable for use across various stages of type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (diarrhea, nausea, vomiting)
- Metallic taste
- Abdominal discomfort
- Lactic acidosis (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin HCI XR CI brief — competitive landscape report
- Metformin HCI XR updates RSS · CI watch RSS
- The University of Texas Health Science Center at San Antonio portfolio CI